M&A Deal Summary

Takeda Acquires Ariad Pharmaceuticals

On January 9, 2017, Takeda acquired life science company Ariad Pharmaceuticals for 5.2B USD

Acquisition Highlights
  • This is Takeda’s 9th transaction in the Life Science sector.
  • This is Takeda’s 4th largest (disclosed) transaction.
  • This is Takeda’s 8th transaction in the United States.
  • This is Takeda’s 2nd transaction in Massachusetts.

M&A Deal Summary
Date 2017-01-09
Target Ariad Pharmaceuticals
Sector Life Science
Buyer(s) Takeda
Deal Type Add-on Acquisition
Deal Value 5.2B USD
Advisor(s) J.P. Morgan Securities
Goldman Sachs (Financial)
Paul, Weiss, Rifkind, Wharton & Garrison (Legal)

Target

Ariad Pharmaceuticals

Cambridge, Massachusetts, United States
Ariad Pharmaceuticals, Inc. is an oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.

Search 202,137 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Takeda

Tokyo, Japan
Category Company
Founded 1781
Sector Life Science
Employees47,347
Revenue 4.03T JPY (2023)
DESCRIPTION
Takeda's corporate headquarters in Tokyo, Japan.
Takeda's corporate headquarters in Tokyo, Japan.

Takeda is a global biopharmaceutical organization committed to improving the health and well-being of people worldwide. Takeda is dedicated to addressing unmet medical needs through the development of innovative and transformative therapies. The Company's diverse portfolio encompasses a wide range of therapeutic areas, including oncology, gastroenterology, rare diseases, neuroscience, and vaccines. Takeda was originally established in 1781 and is based in Tokyo, Japan.

DEAL STATS #
Overall 10 of 18
Sector (Life Science) 9 of 17
Type (Add-on Acquisition) 9 of 15
State (Massachusetts) 2 of 4
Country (United States) 8 of 12
Year (2017) 1 of 1
Size (of disclosed) 4 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-01-05 Baxalta - Biologics Manufacturing Facility

Brooklyn Park, Minnesota, United States

Baxalta - Biologics Manufacturing Facility is a producer of Entyvio® (vedolizumab) and other biologic products.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-05-08 Shire

Dublin, Ireland

Shire plc is a global specialty biopharmaceutical company. Shire plc strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.

Buy £44.0B
Mergr

Product

Company

Legal